Početna › Pločastostanični karcinom glave i vrata
Kliničke studije za Pločastostanični karcinom glave i vrata koje traže sudionike u SAD-u
178 studija za Pločastostanični karcinom glave i vrata traži sudionike na lokacijama širom Sjedinjenih Američkih Država.
Gradovi s najviše studija
- Houston, TX47 studija
- Los Angeles, CA42 studija
- Boston, MA40 studija
- Nashville, TN39 studija
- New York City, NY39 studija
- St. Louis, MO28 studija
- Arlington, VA26 studija
- Philadelphia, PA26 studija
- Chicago, IL26 studija
- Atlanta, GA24 studija
- Pittsburgh, PA22 studija
- New Haven, CT22 studija
- San Antonio, TX22 studija
- Dallas, TX20 studija
- Queens, NY20 studija
- Columbus, OH20 studija
- Portland, OR19 studija
- Cleveland, OH18 studija
- Durham, NC17 studija
- Orlando, FL16 studija
- Baldwin Park, CA16 studija
- Detroit, MI15 studija
- Edison, NJ15 studija
- Baltimore, MD15 studija
- Tampa, FL15 studija
- Grand Rapids, MI15 studija
- Cincinnati, OH14 studija
- Miami, FL14 studija
- San Diego, CA14 studija
- Charleston, SC14 studija
- Santa Monica, CA13 studija
- Milwaukee, WI13 studija
- Omaha, NE13 studija
- Oklahoma City, OK13 studija
- Rochester, MN12 studija
- Jacksonville, FL12 studija
- Richmond, VA12 studija
- Cedar Rapids, IA12 studija
- Ann Arbor, MI12 studija
- West Valley City, UT11 studija
Po državama
- Alabama7 studija
- Arizona18 studija
- Arkansas11 studija
- Colorado23 studija
- Connecticut24 studija
- Delaware3 studija
- Distrikt Columbia9 studija
- Florida53 studija
- Georgia26 studija
- Idaho4 studija
- Illinois30 studija
- Indiana13 studija
- Iowa14 studija
- Kalifornija72 studija
- Kansas9 studija
- Kentucky16 studija
- Louisiana6 studija
- Maryland18 studija
- Massachusetts42 studija
- Michigan36 studija
- Minnesota23 studija
- Missouri29 studija
- Montana5 studija
- Nebraska15 studija
- Nevada4 studija
- New Hampshire3 studija
- New Jersey26 studija
- New Mexico3 studija
- New York54 studija
- North Carolina27 studija
- North Dakota6 studija
- Ohio46 studija
- Oklahoma14 studija
- Oregon19 studija
- Pennsylvania41 studija
- Rhode Island7 studija
- South Carolina21 studija
- South Dakota9 studija
- Tennessee43 studija
- Texas69 studija
- Utah21 studija
- Vermont3 studija
- Virginia42 studija
- Washington18 studija
- Wisconsin15 studija
Nedavno ažurirane studije
Službeni tekst studije (engleski)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06992427FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06788990A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06465069Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT06265285Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT05176483177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07189871A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07090499Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06589804A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07085091A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07814248A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07744126Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT07360314A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 29. ruj 2026. · NCT05877599A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
U tijeku regrutacijaFaza 1
Od 18 do 74 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT07219212BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT07276399JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
U tijeku regrutacijaFaza 3
Od 60 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT04892173Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06980038A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06385080A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT07229313Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06047379Intratumoral N17350 in Advanced Solid Tumors
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 23. ruj 2026. · NCT07339176Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
U tijeku regrutacijaFaza 2
Od 18 do 79 godina · Oba spola · Ažurirano 22. ruj 2026. · NCT04671667Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT05983432Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT06736379Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.